| Title: |
Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). |
| Authors: |
MacDonald, TM; Hawkey, CJ; Ford, I; McMurray, JJV; Scheiman, JM; Hallas, J; Findlay, E; Grobbee, DE; Hobbs, FDR; Ralston, SH; Reid, DM; Walters, MR; Webster, J; Ruschitzka, F; Ritchie, LD; Perez-Gutthann, S; Connolly, E; Greenlaw, N; Wilson, A; Wei, L; Mackenzie, IS |
| Publisher Information: |
Oxford University Press |
| Publication Year: |
2018 |
| Collection: |
Oxford University Research Archive (ORA) |
| Description: |
Background Selective cyclooxygenase-2 inhibitors and conventional non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) have been associated with adverse cardiovascular (CV) effects. We compared the CV safety of switching to celecoxib vs. continuing nsNSAID therapy in a European setting. Method Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID. The primary endpoint was hospitalization for non-fatal myocardial infarction or other biomarker positive acute coronary syndrome, non-fatal stroke or CV death analysed using a Cox model with a pre-specified non-inferiority limit of 1.4 for the hazard ratio (HR). Results In total, 7297 participants were randomized. During a median 3-year follow-up, fewer subjects than expected developed an on-treatment (OT) primary CV event and the rate was similar for celecoxib, 0.95 per 100 patientyears, and nsNSAIDs, 0.86 per 100 patient-years (HR ¼1.12, 95% confidence interval, 0.81–1.55; P ¼0.50). Comparable intention-to-treat (ITT) rates were 1.14 per 100 patient-years with celecoxib and 1.10 per 100 patient-years with nsNSAIDs (HR¼1.04; 95% confidence interval, 0.81–1.33; P¼0.75). Pre-specified non-inferiority was achieved in the ITT analysis. The upper bound of the 95% confidence limit for the absolute increase in OT risk associated with celecoxib treatment was two primary events per 1000 patient-years exposure. There were only 15 adjudicated secondary upper gastrointestinal complication endpoints (0.078/100 patient-years on celecoxib vs. 0.053 on nsNSAIDs OT, 0.078 vs. 0.053 ITT). More gastrointestinal serious adverse reactions and haematological adverse reactions were reported on nsNSAIDs than celecoxib, but more patients withdrew from celecoxib than nsNSAIDs (50.9% patients vs. 30.2%; P |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://doi.org/10.1093/eurheartj/ehw387 |
| DOI: |
10.1093/eurheartj/ehw387 |
| Availability: |
https://doi.org/10.1093/eurheartj/ehw387; https://ora.ox.ac.uk/objects/uuid:af570b27-6c82-43a9-b355-919b572066d9 |
| Rights: |
info:eu-repo/semantics/openAccess ; CC Attribution-NonCommercial (CC BY-NC) |
| Accession Number: |
edsbas.4613F242 |
| Database: |
BASE |